Cargando…
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
Background: Currently, limited data on targeted therapy and immunotherapy sequencing in patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032972/ https://www.ncbi.nlm.nih.gov/pubmed/35456332 http://dx.doi.org/10.3390/jcm11082239 |
_version_ | 1784692776681603072 |
---|---|
author | Rogala, Paweł Czarnecka, Anna M. Cybulska-Stopa, Bożena Ostaszewski, Krzysztof Piejko, Karolina Ziętek, Marcin Dziura, Robert Rutkowska, Ewa Galus, Łukasz Kempa-Kamińska, Natasza Calik, Jacek Sałek-Zań, Agata Zemełka, Tomasz Bal, Wiesław Kamycka, Agnieszka Świtaj, Tomasz Kamińska-Winciorek, Grażyna Suwiński, Rafał Mackiewicz, Jacek Rutkowski, Piotr |
author_facet | Rogala, Paweł Czarnecka, Anna M. Cybulska-Stopa, Bożena Ostaszewski, Krzysztof Piejko, Karolina Ziętek, Marcin Dziura, Robert Rutkowska, Ewa Galus, Łukasz Kempa-Kamińska, Natasza Calik, Jacek Sałek-Zań, Agata Zemełka, Tomasz Bal, Wiesław Kamycka, Agnieszka Świtaj, Tomasz Kamińska-Winciorek, Grażyna Suwiński, Rafał Mackiewicz, Jacek Rutkowski, Piotr |
author_sort | Rogala, Paweł |
collection | PubMed |
description | Background: Currently, limited data on targeted therapy and immunotherapy sequencing in patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the characteristics of patients who completed sequential treatment is needed. Methods: The primary objective of this study was to analyze the efficacy of BRAFi/MEKi activity as second-line therapy in patients with advanced melanoma. We also aimed to describe the clinical characteristics of patients with advanced melanoma who were treated sequentially with immunotherapy and targeted therapy. We enrolled 97 patients treated between 1st December 2015 and 31st December 2020 with first-line immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors; and for the second-line treatment with at least one cycle of BRAFi/MEKi therapy with follow-up through 31 January 2022. Results: Median OS since first-line treatment initiation was 19.9 months and 12.8 months since initiation of BRAFi/MEKi treatment. All BRAFi/MRKi combinations were similarly effective. Median progression free survival (PFS) was 7.5 months since initiation of any BRAFi/MEKi treatment. Conclusions: BRAFi/MEKi therapy is effective in the second-line in advanced and metastatic melanoma patients. For the first time, the efficacy of all BRAFi/MEKi combinations as second-line therapy is shown. |
format | Online Article Text |
id | pubmed-9032972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90329722022-04-23 Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence Rogala, Paweł Czarnecka, Anna M. Cybulska-Stopa, Bożena Ostaszewski, Krzysztof Piejko, Karolina Ziętek, Marcin Dziura, Robert Rutkowska, Ewa Galus, Łukasz Kempa-Kamińska, Natasza Calik, Jacek Sałek-Zań, Agata Zemełka, Tomasz Bal, Wiesław Kamycka, Agnieszka Świtaj, Tomasz Kamińska-Winciorek, Grażyna Suwiński, Rafał Mackiewicz, Jacek Rutkowski, Piotr J Clin Med Article Background: Currently, limited data on targeted therapy and immunotherapy sequencing in patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the characteristics of patients who completed sequential treatment is needed. Methods: The primary objective of this study was to analyze the efficacy of BRAFi/MEKi activity as second-line therapy in patients with advanced melanoma. We also aimed to describe the clinical characteristics of patients with advanced melanoma who were treated sequentially with immunotherapy and targeted therapy. We enrolled 97 patients treated between 1st December 2015 and 31st December 2020 with first-line immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors; and for the second-line treatment with at least one cycle of BRAFi/MEKi therapy with follow-up through 31 January 2022. Results: Median OS since first-line treatment initiation was 19.9 months and 12.8 months since initiation of BRAFi/MEKi treatment. All BRAFi/MRKi combinations were similarly effective. Median progression free survival (PFS) was 7.5 months since initiation of any BRAFi/MEKi treatment. Conclusions: BRAFi/MEKi therapy is effective in the second-line in advanced and metastatic melanoma patients. For the first time, the efficacy of all BRAFi/MEKi combinations as second-line therapy is shown. MDPI 2022-04-17 /pmc/articles/PMC9032972/ /pubmed/35456332 http://dx.doi.org/10.3390/jcm11082239 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rogala, Paweł Czarnecka, Anna M. Cybulska-Stopa, Bożena Ostaszewski, Krzysztof Piejko, Karolina Ziętek, Marcin Dziura, Robert Rutkowska, Ewa Galus, Łukasz Kempa-Kamińska, Natasza Calik, Jacek Sałek-Zań, Agata Zemełka, Tomasz Bal, Wiesław Kamycka, Agnieszka Świtaj, Tomasz Kamińska-Winciorek, Grażyna Suwiński, Rafał Mackiewicz, Jacek Rutkowski, Piotr Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence |
title | Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence |
title_full | Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence |
title_fullStr | Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence |
title_full_unstemmed | Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence |
title_short | Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence |
title_sort | long-term outcomes of targeted therapy after first-line immunotherapy in braf-mutated advanced cutaneous melanoma patients—real-world evidence |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032972/ https://www.ncbi.nlm.nih.gov/pubmed/35456332 http://dx.doi.org/10.3390/jcm11082239 |
work_keys_str_mv | AT rogalapaweł longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT czarneckaannam longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT cybulskastopabozena longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT ostaszewskikrzysztof longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT piejkokarolina longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT zietekmarcin longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT dziurarobert longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT rutkowskaewa longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT galusłukasz longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT kempakaminskanatasza longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT calikjacek longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT sałekzanagata longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT zemełkatomasz longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT balwiesław longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT kamyckaagnieszka longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT switajtomasz longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT kaminskawinciorekgrazyna longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT suwinskirafał longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT mackiewiczjacek longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence AT rutkowskipiotr longtermoutcomesoftargetedtherapyafterfirstlineimmunotherapyinbrafmutatedadvancedcutaneousmelanomapatientsrealworldevidence |